logo

Malaysia Diabetes Care Drugs Market Size (2024 - 2029)

The Malaysia Diabetes Drugs Market is projected to experience growth over the forecast period, driven by an increasing prevalence of diabetes, particularly among younger individuals. This rising incidence contributes to a greater healthcare burden, as diabetes is linked to severe complications such as heart disease and kidney issues. The insulin segment holds a significant portion of the market, characterized by intense competition among a limited number of manufacturers striving to meet patient needs with high-quality products.

Home Market Analysis Healthcare Research Pharmaceuticals Research Disease Specific Drugs Research Chronic Disorder Drugs Research Diabetes Care Drugs Research Diabetes Drugs Market in Malaysia Market Size

Market Size of Malaysia Diabetes Care Drugs Industry

Malaysia Diabetes Care Drugs Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Market Size (2024) USD 389.13 Million
Market Size (2029) USD 423.21 Million
CAGR (2024 - 2029) 3.10 %

Major Players

Malaysia Diabetes Care Drugs Market Major Players

*Disclaimer: Major Players sorted in no particular order

Malaysia Diabetes Drugs Market Analysis

The Malaysia Diabetes Care Drugs Market size is estimated at USD 389.13 million in 2024, and is expected to reach USD 423.21 million by 2029, growing at a CAGR of 3.10% during the forecast period (2024-2029).

Malaysia's Ministry of Health reported 5,809 new COVID-19 cases in 24 hours, comprising 5,782 locally infected and 27 imported cases, increasing the national total to 2,541,147. So far, about 78.4 percent of the Malaysian population has gotten at least one dose of the COVID-19 vaccine, with 75.9 percent completely vaccinated. According to the Health Ministry, four out of every ten patients who died from COVID-19 in Malaysia this year had diabetes. Diabetes affects one in every five Malaysians, or around 3.9 million persons aged 18 and up.

The number of young diabetics is increasing. Diabetes is becoming more common in younger individuals, with the number of diabetics aged 18 to 40 more than tripling in the last 15 years. The growing population of diabetics means a greater burden of the illness and its consequences, including heart disease, stroke, blindness, chronic kidney disease, and lower limb amputation.

In reality, underlying comorbidities account for most coronavirus mortality in Malaysia, with diabetes and hypertension leading the list.

In terms of medicines, the insulin category commands a sizable market share. Over 100 million people worldwide use insulin, including all persons with Type 1 diabetes and 10% to 25% of people with Type 2 diabetes. Insulin production is extremely sophisticated, and only a few insulin manufacturers are on the market. As a result, there is fierce rivalry among these producers, who continually strive to satisfy patients' demands by providing the highest-quality insulin.

Malaysia Diabetes Drugs Industry Segmentation

Diabetes or diabetes mellitus describes a group of metabolic disorders characterized by a high blood sugar level in a person. With diabetes, the body either does not produce enough insulin the body's cells do not respond properly to insulin, or both. Malaysia's diabetes care drugs market witnessed USD 339 million in the current year and is anticipated to register a cagr of over 3% during the forecast period. Malaysia's diabetes care drugs market is segmented into drugs. The report offers the market size in value terms in USD for all the abovementioned segments.

Oral Anti-diabetic drugs
Biguanides
Metformin
Alpha-Glucosidase Inhibitors
Alpha-Glucosidase Inhibitors
Dopamine D2 receptor agonist
Bromocriptin
SGLT-2 inhibitors
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
DPP-4 inhibitors
Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia/Nesina(Alogliptin)
Galvus (Vildagliptin)
Sulfonylureas
Sulfonylureas
Meglitinides
Meglitinides
Insulins
Basal or Long Acting Insulins
Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Toujeo (Insulin Glargine)
Tresiba (Insulin Degludec)
Basaglar (Insulin Glargine)
Bolus or Fast Acting Insulins
NovoRapid/Novolog (Insulin Aspart)
Humalog (Insulin Lispro)
Apidra (Insulin Glulisine)
Traditional Human Insulins
Novolin/Actrapid/Insulatard
Humulin
Insuman
Biosimilar Insulins
Insulin Glargine Biosimilars
Human Insulin Biosimilars
Combination drugs
Insulin combinations
NovoMix (Biphasic Insulin Aspart)
Ryzodeg (Insulin Degludec and Insulin Aspart)
Xultophy (Insulin Degludec and Liraglutide)
Oral Combinations
Janumet (Sitagliptin and Metformin)
Non-Insulin Injectable drugs
GLP-1 receptor agonists
Victoza (Liraglutide)
Byetta (Exenatide)
Bydureon (Exenatide)
Trulicity (Dulaglutide)
Lyxumia (Lixisenatide)
Amylin Analogue
Symlin (Pramlintide)
Need A Different Region Or Segment?
Customize Now

Malaysia Diabetes Care Drugs Market Size Summary

The Malaysia diabetes drugs market is poised for growth, driven by the increasing prevalence of diabetes and related health issues in the country. With a significant portion of the population affected, diabetes has become a major public health concern, contributing to a high burden of comorbidities such as heart disease and chronic kidney disease. The market is characterized by a strong demand for both insulin and oral anti-diabetes drugs, with insulin therapy being a critical component of diabetes management. The market landscape is moderately fragmented, with major players like Novo-Nordisk, Sanofi, and AstraZeneca leading the charge in the insulin segment, while the oral drugs market sees a higher presence of generic competitors. The competitive environment is intense, as companies strive to innovate and expand their market share, particularly in emerging economies like Malaysia.

The Malaysian government's proactive approach in implementing diabetes prevention and management programs is expected to further stimulate market growth. Initiatives aimed at enhancing public awareness and improving disease control are crucial, given the rising rates of obesity and sedentary lifestyles contributing to the diabetes epidemic. The market is also witnessing advancements in drug development, with new therapies such as Tirzepatide and innovative delivery methods like oral insulin capsules showing promise. These developments, coupled with the government's support for management devices, are likely to drive the market forward during the forecast period. As the demand for effective diabetes management solutions continues to rise, the market is set to expand, offering opportunities for both established and emerging players.

Explore More

Malaysia Diabetes Care Drugs Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

    3. 1.3 Market Restraints

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Suppliers

      2. 1.4.2 Bargaining Power of Consumers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products and Services

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 Oral Anti-diabetic drugs

      1. 2.1.1 Biguanides

        1. 2.1.1.1 Metformin

      2. 2.1.2 Alpha-Glucosidase Inhibitors

        1. 2.1.2.1 Alpha-Glucosidase Inhibitors

      3. 2.1.3 Dopamine D2 receptor agonist

        1. 2.1.3.1 Bromocriptin

      4. 2.1.4 SGLT-2 inhibitors

        1. 2.1.4.1 Invokana (Canagliflozin)

        2. 2.1.4.2 Jardiance (Empagliflozin)

        3. 2.1.4.3 Farxiga/Forxiga (Dapagliflozin)

        4. 2.1.4.4 Suglat (Ipragliflozin)

      5. 2.1.5 DPP-4 inhibitors

        1. 2.1.5.1 Onglyza (Saxagliptin)

        2. 2.1.5.2 Tradjenta (Linagliptin)

        3. 2.1.5.3 Vipidia/Nesina(Alogliptin)

        4. 2.1.5.4 Galvus (Vildagliptin)

      6. 2.1.6 Sulfonylureas

        1. 2.1.6.1 Sulfonylureas

      7. 2.1.7 Meglitinides

        1. 2.1.7.1 Meglitinides

    2. 2.2 Insulins

      1. 2.2.1 Basal or Long Acting Insulins

        1. 2.2.1.1 Lantus (Insulin Glargine)

        2. 2.2.1.2 Levemir (Insulin Detemir)

        3. 2.2.1.3 Toujeo (Insulin Glargine)

        4. 2.2.1.4 Tresiba (Insulin Degludec)

        5. 2.2.1.5 Basaglar (Insulin Glargine)

      2. 2.2.2 Bolus or Fast Acting Insulins

        1. 2.2.2.1 NovoRapid/Novolog (Insulin Aspart)

        2. 2.2.2.2 Humalog (Insulin Lispro)

        3. 2.2.2.3 Apidra (Insulin Glulisine)

      3. 2.2.3 Traditional Human Insulins

        1. 2.2.3.1 Novolin/Actrapid/Insulatard

        2. 2.2.3.2 Humulin

        3. 2.2.3.3 Insuman

      4. 2.2.4 Biosimilar Insulins

        1. 2.2.4.1 Insulin Glargine Biosimilars

        2. 2.2.4.2 Human Insulin Biosimilars

    3. 2.3 Combination drugs

      1. 2.3.1 Insulin combinations

        1. 2.3.1.1 NovoMix (Biphasic Insulin Aspart)

        2. 2.3.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)

        3. 2.3.1.3 Xultophy (Insulin Degludec and Liraglutide)

      2. 2.3.2 Oral Combinations

        1. 2.3.2.1 Janumet (Sitagliptin and Metformin)

    4. 2.4 Non-Insulin Injectable drugs

      1. 2.4.1 GLP-1 receptor agonists

        1. 2.4.1.1 Victoza (Liraglutide)

        2. 2.4.1.2 Byetta (Exenatide)

        3. 2.4.1.3 Bydureon (Exenatide)

        4. 2.4.1.4 Trulicity (Dulaglutide)

        5. 2.4.1.5 Lyxumia (Lixisenatide)

      2. 2.4.2 Amylin Analogue

        1. 2.4.2.1 Symlin (Pramlintide)

Malaysia Diabetes Care Drugs Market Size FAQs

The Malaysia Diabetes Care Drugs Market size is expected to reach USD 389.13 million in 2024 and grow at a CAGR of 3.10% to reach USD 423.21 million by 2029.

In 2024, the Malaysia Diabetes Care Drugs Market size is expected to reach USD 389.13 million.

Malaysia Diabetes Drugs Market Report Snapshots

Malaysia Diabetes Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)